The Substance Abuse and Mental Health Services Administration yesterday issued guidance for health care and addiction professionals using methadone, naltrexone or buprenorphine to treat patients with opioid use disorder. Mandated by the Comprehensive Addiction and Recovery Act, the guidance offers appropriate prescribing practices and strategies for supporting patients. It also educates patients, families and the general public about the medications. “We know that people can and do recover from opioid use disorders when they receive appropriate treatment, and medication-assisted treatment’s success in treating opioid use disorders is well documented,” said Elinore McCance-Katz, M.D., assistant secretary for mental health and substance use at the Department of Health and Human Services. For an AHA toolkit and other resources to help hospitals and health systems tackle the opioid crisis, visit www.aha.org/opioidtoolkit.

Related News Articles

Headline
The House Committee on Oversight and Reform today held the third in a series of hearings examining solutions to the opioid epidemic, which focused on the…
Headline
The Food and Drug Administration today published a notice seeking comment through July 30 on a potential change to the Opioid Analgesic Risk Evaluation and…
Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
Laws that allow pharmacists to dispense the opioid antidote naloxone without a physician’s prescription are associated with a sharp reduction in fatal opioid-…
Headline
The White House Office of National Drug Control Policy seeks by 2022 to reduce drug overdose deaths and youth illicit drug use by 15 percent and opioid…
Perspective
Investing in our country’s health infrastructure is the right move to make.